Literature DB >> 19925895

Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity.

Samuel Gourion-Arsiquaud1, Matthew R Allen, David B Burr, Deepak Vashishth, Simon Y Tang, Adele L Boskey.   

Abstract

Bone loss and alterations in bone quality are major causes leading to bone fragility in postmenopausal women. Although bisphosphonates are well known to reduce bone turnover and prevent bone loss in postmenopausal osteoporosis, their effects on other bone properties are not fully characterized. Changes in bone mineral and matrix properties may contribute to the anti-fracture efficacy observed with bisphosphonate treatments. The aim of this work was to analyze the effect of a 1-year treatment with either alendronate or risedronate, at low and high doses, on spatially resolved bone material and compositional properties that could contribute to the fracture efficacy of these agents. Distal tibias from 30 normal beagles that had been treated daily for 1 year with oral doses of vehicle (Veh), alendronate (Aln) at 0.2 or 1 mg/kg, and risedronate (Ris) at 0.1 or 0.5 mg/kg were analyzed by Fourier Transform Infrared imaging (FTIRI) to assess the changes in both mineral and matrix properties in discrete bone areas. The widths at half maximum of the pixel histograms for each FTIRI parameter were used to assess the heterogeneity of the bone tissue. Aln and Ris increased the mineral content and the collagen maturity mainly in cancellous bone and at the endocortical surface. Significant differences were observed in the mineral content and in the hydroxyapatite crystallinity distribution in bone tissue, which can contribute to reduced ductility and micro-crack accumulation. No significant differences were observed between low and high dose nor between Aln and Ris treatments. These results show that pharmacologic suppression of bone turnover increases the mineral and matrix bone tissue maturity in normal cancellous and endocortical bone areas where bone turnover is higher. These positive effects for decreased fracture risk are also associated with a loss of bone heterogeneity that could be one factor contributing to increased bone tissue brittleness and micro-crack accumulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19925895      PMCID: PMC2823979          DOI: 10.1016/j.bone.2009.11.011

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  63 in total

Review 1.  The role of collagen in bone strength.

Authors:  S Viguet-Carrin; P Garnero; P D Delmas
Journal:  Osteoporos Int       Date:  2005-12-09       Impact factor: 4.507

2.  Spatial variation in osteonal bone properties relative to tissue and animal age.

Authors:  Samuel Gourion-Arsiquaud; Jayme C Burket; Lorena M Havill; Edward DiCarlo; Stephen B Doty; Richard Mendelsohn; Marjolein C H van der Meulen; Adele L Boskey
Journal:  J Bone Miner Res       Date:  2009-07       Impact factor: 6.741

3.  Biomechanical effect of mineral heterogeneity in trabecular bone.

Authors:  G A P Renders; L Mulder; G E J Langenbach; L J van Ruijven; T M G J van Eijden
Journal:  J Biomech       Date:  2008-08-22       Impact factor: 2.712

4.  Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.

Authors:  Erich Durchschlag; Eleftherios P Paschalis; Ruth Zoehrer; Paul Roschger; Peter Fratzl; Robert Recker; Roger Phipps; Klaus Klaushofer
Journal:  J Bone Miner Res       Date:  2006-10       Impact factor: 6.741

5.  Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats.

Authors:  S Bourrin; P Ammann; J P Bonjour; R Rizzoli
Journal:  Bone       Date:  2002-01       Impact factor: 4.398

Review 6.  Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance.

Authors:  L Knott; A J Bailey
Journal:  Bone       Date:  1998-03       Impact factor: 4.398

7.  Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra.

Authors:  Satoshi Komatsubara; Satoshi Mori; Tasuku Mashiba; Masako Ito; Jiliang Li; Yoshio Kaji; Tomoyuki Akiyama; Kensaku Miyamoto; Yongping Cao; Jun Kawanishi; Hiromichi Norimatsu
Journal:  J Bone Miner Res       Date:  2003-03       Impact factor: 6.741

8.  Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties.

Authors:  J S Day; M Ding; P Bednarz; J C van der Linden; T Mashiba; T Hirano; C C Johnston; D B Burr; I Hvid; D R Sumner; H Weinans
Journal:  J Orthop Res       Date:  2004-05       Impact factor: 3.494

Review 9.  Bisphosphonates: mechanism of action and role in clinical practice.

Authors:  Matthew T Drake; Bart L Clarke; Suneep Khosla
Journal:  Mayo Clin Proc       Date:  2008-09       Impact factor: 7.616

10.  Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs.

Authors:  M Saito; S Mori; T Mashiba; S Komatsubara; K Marumo
Journal:  Osteoporos Int       Date:  2008-03-29       Impact factor: 5.071

View more
  59 in total

Review 1.  Aging and bone.

Authors:  A L Boskey; R Coleman
Journal:  J Dent Res       Date:  2010-10-05       Impact factor: 6.116

2.  Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures.

Authors:  Eve Donnelly; Dennis S Meredith; Joseph T Nguyen; Brian P Gladnick; Brian J Rebolledo; Andre D Shaffer; Dean G Lorich; Joseph M Lane; Adele L Boskey
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741

Review 3.  Raman assessment of bone quality.

Authors:  Michael D Morris; Gurjit S Mandair
Journal:  Clin Orthop Relat Res       Date:  2011-08       Impact factor: 4.176

Review 4.  Infrared assessment of bone quality: a review.

Authors:  Eleftherios P Paschalis; Richard Mendelsohn; Adele L Boskey
Journal:  Clin Orthop Relat Res       Date:  2011-08       Impact factor: 4.176

5.  Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects.

Authors:  Crystal K Tjhia; Clarita V Odvina; D Sudhaker Rao; Susan M Stover; Xiang Wang; David P Fyhrie
Journal:  Bone       Date:  2011-09-18       Impact factor: 4.398

Review 6.  Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability.

Authors:  Teresita Bellido; Lilian I Plotkin
Journal:  Bone       Date:  2010-08-18       Impact factor: 4.398

Review 7.  Atypical femoral fractures: epidemiology, etiology, and patient management.

Authors:  Eve Donnelly; Anas Saleh; Aasis Unnanuntana; Joseph M Lane
Journal:  Curr Opin Support Palliat Care       Date:  2012-09       Impact factor: 2.302

8.  Variations in nanomechanical properties and tissue composition within trabeculae from an ovine model of osteoporosis and treatment.

Authors:  Jayme C Burket; Daniel J Brooks; Jennifer M MacLeay; Shefford P Baker; Adele L Boskey; Marjolein C H van der Meulen
Journal:  Bone       Date:  2012-10-23       Impact factor: 4.398

9.  High-scale yield of nano hydroxyapatite through combination of mechanical activation and chemical dispersion.

Authors:  Xueling Gao; Chunchu Dai; Weiwei Liu; Yumei Liu; Ru Shen; Xiaotong Zheng; Ke Duan; Jie Weng; Shuxin Qu
Journal:  J Mater Sci Mater Med       Date:  2017-04-21       Impact factor: 3.896

10.  Young's modulus and hardness of human trabecular bone with bisphosphonate treatment durations up to 20 years.

Authors:  D Pienkowski; C L Wood; H H Malluche
Journal:  Osteoporos Int       Date:  2018-11-28       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.